Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

Summary

This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.

Timeline

Start

2005-11

Primary completion

2006-02

Completion

2006-02

Drugs

Indications